Patents by Inventor Ruben Tommasi
Ruben Tommasi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11046694Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.Type: GrantFiled: May 8, 2018Date of Patent: June 29, 2021Assignee: Entasis Therapeutics, Inc.Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
-
Patent number: 10800778Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.Type: GrantFiled: September 15, 2017Date of Patent: October 13, 2020Assignee: Entasis Therapeutics LimitedInventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
-
Publication number: 20200165251Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.Type: ApplicationFiled: May 8, 2018Publication date: May 28, 2020Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
-
Patent number: 10376499Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 9, 2018Date of Patent: August 13, 2019Assignee: Entasis Therapeutics LimitedInventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Publication number: 20190202832Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.Type: ApplicationFiled: September 15, 2017Publication date: July 4, 2019Applicants: Entasis Therapeutics Limited, Entasis Therapeutics LimitedInventors: Gregory S. Basarab, Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, Bill Moss, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
-
Publication number: 20180289681Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 9, 2018Publication date: October 11, 2018Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Patent number: 9968593Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 17, 2015Date of Patent: May 15, 2018Assignee: Entasis Therapeutics LimitedInventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Publication number: 20180000800Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 17, 2015Publication date: January 4, 2018Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
-
Patent number: 8476286Abstract: Use of compound of formula (I), wherein, is, or, and wherein the symbols are as defined, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.Type: GrantFiled: June 14, 2002Date of Patent: July 2, 2013Assignee: Novartis AGInventors: René Beerli, Ruben A Tommasi, Sven Weiler, Leo Widler
-
Publication number: 20090197856Abstract: Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.Type: ApplicationFiled: December 19, 2008Publication date: August 6, 2009Inventors: Salvador G. Alvarez, Janos Botyanszki, Joseph de los Angeles, Jiping Fu, Roger Fujimoto, Joshua Michael Gralapp, Ronald Conrad Griffith, Peichao Lu, Son Minh Pham, Christopher Don Roberts, Franz Ulrich Schmitz, Mohindra Seepersaud, Ruben Tommasi, Adam Christopher Villa, Sompong Wattanasin, Aregahagn Yifru, Rui Zheng, Xiaoling Zheng
-
Publication number: 20080027060Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.Type: ApplicationFiled: August 7, 2007Publication date: January 31, 2008Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Cowen, Paul Greenspan, Leslie McQuire, Ruben Tommasi, John van Duzer
-
Publication number: 20070060569Abstract: Compound of the formula wherein R represents OH or NHOH; R1 represents hydrogen, optically substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid or from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyrylsulfonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.Type: ApplicationFiled: November 2, 2006Publication date: March 15, 2007Inventors: Roger Fujimoto, Leslie McQuire, Lauren Monovich, Philippe Nantermet, David Parker, Leslie Robinson, Jerry Skiles, Ruben Tommasi
-
Patent number: 6289914Abstract: This invention refers to a microsplitter in flow systems especially used for separation techniques in analytical chemistry such as microliquid chromatography (MLC), high pressure liquid chromatography (HPLC) and ancillary techniques. The splitter system comprises a microsplitter and a micromixer which are connected by a microbore tubing. A high collection rate and high resolution of the sample peak are achieved by the proper choice of tubing length and diameters and the use of a back pressure regulator to obtain a controlled split ratio.Type: GrantFiled: August 16, 2000Date of Patent: September 18, 2001Assignee: Novartis AGInventor: Ruben A. Tommasi
-
Patent number: 6169181Abstract: The present invention relates to compounds of formula I and II which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus.Type: GrantFiled: November 9, 1998Date of Patent: January 2, 2001Assignee: Pharmacia & Upjohn CompanyInventors: Karen Rene Romines, Gordon L. Bundy, Theresa M. Schwartz, Ruben A. Tommasi, Joseph W. Strohbach, Steven Ronald Turner, Suvit Thaisrivongs, Paul Adrian Aristoff, Paul D. Johnson, Harvey Irving Skulnick, Louis L. Skaletzky, David John Anderson, Joel Morris, Ronald B. Gammill, George P. Luke
-
Patent number: 6060600Abstract: This application discloses novel tetronic acids for the treatment of AIDS and other diseases caused by retroviruses.Type: GrantFiled: September 17, 1997Date of Patent: May 9, 2000Assignee: Pharmacia & Upjohn CompanyInventors: Robert A. Chruscial, Linda L. Maggiora, Suvit Thaisrivongs, James M. Tustin, Clark W. Smith, Ruben A. Tommasi, Paul A. Aristoff, Harvey I. Skulnick, W. Jeffrey Howe
-
Patent number: 5977169Abstract: This invention comprises novel substituted tetronic acid type compounds, 2, 4(3H, 5H)-furandiones, that are useful for the inhibition of the HIV protease enzyme. The compounds may be useful for the treatment of a person with AIDS or AIDS related diseases. The compounds may be used in the attempt to retard the further replication of any retrovirus containing the aspartyl protease enzyme. Compounds are represented by the formula below.Type: GrantFiled: July 28, 1997Date of Patent: November 2, 1999Inventors: Robert A. Chrusciel, Linda L. Maggiora, Suvit Thaisrivongs, James M. Tustin, Clark W. Smith, Ruben A. Tommasi, Paul A. Aristoff, Harvey I. Skulnick, W. Jeffrey Howe, Gordon L. Bundy
-
Patent number: 5852195Abstract: The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl?b!pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV).Type: GrantFiled: November 4, 1996Date of Patent: December 22, 1998Assignee: Pharmacia & Upjohn CompanyInventors: Karen Rene Romines, Gordon L. Bundy, Theresa M. Schwartz, Ruben A. Tommasi, Joseph W. Strohbach, Steven Ronald Turner, Suvit Thaisrivongs, Paul Adrian Aristoff, Paul D. Johnson, Harvey Irving Skulnick, Louis L. Skaletzky, David John Anderson, Joel Morris, Ronald B. Gammill, George P. Luke